Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety.

To elaborate, significant improvement was observed among the SMA 1 patients ( Figure 1 A), a positive trend was observed among the SMA 3p subpopulation ( Figure 1 B), whilst there was practically no change when nusinersen was introduced in the SMA 3 patients after the age of 18 years ( Figure 1 C).

also in 3,956 other papers

When a more in-depth look is given to the SMA 1 subpopulation results ( Table 2 , Figure 1 A), there is a potential positive trend in favour of risdiplam for motor effectiveness (e.g., since the p value is very close to significance on a relatively small sample).

also in 54 other papers